Lexaria Bioscience Corp. LXRP Archives - Page 21 of 27

FridayApr 06, 2018 3:23 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Technology Could Revolutionize Smokeless Tobacco

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) revolutionary DehydraTECH™ technology has proven to be effective in cannabinoid delivery and is now undergoing testing for nicotine. An article discussing the company reads: “Lexaria is now looking to out-license its DehydraTECH to third-party partners in the tobacco industry. These partnerships could pave the way for a healthier smoke-free option for the one billion smokers worldwide. Lexaria is the only company in the world that holds a patent for this oral technology, including the pill. A new U.S. patent award protects this nicotine delivery system, creating a path for what could be the world’s…

WednesdayFeb 28, 2018 1:16 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is Uniquely Positioned within the Cannabis Industry

Cannabis deals in Canada cross the billion-dollar mark DehydraTech™ offers new and innovative methods of oral delivery Committed to high quality products using revolutionary technology The only company in the world with patents for this innovative edible technology Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) expects to benefit significantly as cannabis deals in Canada cross the billion-dollar mark in anticipation of the legalization of recreational cannabis, which is only months away (http://ibn.fm/n7ztX). Its newly developed oral digestion technology, DehydraTECH™, is a complementary layer that works with other R&D being done on cannaboids. LXRP has been awarded a patent in the…

TuesdayFeb 27, 2018 10:13 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Licensing Agreement with Biolog, Inc.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced its entry into a definitive technology licensing agreement with Los Angeles-based, privately-held Biolog, Inc. Under the terms of this agreement, Lexaria will provide its patented DehydraTECH™ technology in an effort to empower a unique set of next-generation food and beverage cannabis infusion products to be sold in the United States. “The versatility of Lexaria's DehyrdaTECH™ technology is witnessed through its adoption to deliver vitamins in a nationally-available consumer product, or cannabinoids in many U.S. states,” Chris…

MondayFeb 26, 2018 10:29 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Global Licensing Agreement with Neutrisci International Inc. (TSX-V: NU) (OTCQB: NRXCF)

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it has entered an agreement with NeutriSci International Inc. (TSX-V: NU) (OTCQB: NRXCF) resulting in NeutriSci now having 100% ownership of Ambarii Trade Corporation. Lexaria has also granted to NeutriSci an Intellectual Property License and Supply Agreement for the manufacturing and sale of CBD based products. Per the License Agreement, NeutriSci will remain focused on the development and sales of its existing and pipeline products that include Lexaria's technology for enhancing palatability and bioavailability of beneficial non-psychoactive cannabinoids. Lexaria will receive continuing royalty revenues from the sales generated by these products.…

ThursdayFeb 15, 2018 4:21 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP): IP Portfolio, Licensing and R&D are Keys to Growth in 2018

LXRP has global patents or patents-pending in more than 40 countries, including the U.S., Australia, China, the European Union and Canada Company is working through a C$250,000 budget for an 18-month collaborative research agreement with the National Research Council Licensing is a revenue generator, with LXRP offering to license its disruptive DehydraTECH™ technology in countries where it is patented or patent-pending Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is generating revenue and knowledge through both licensing of its IP portfolio and advancement of R&D projects. It already has patents and multiple patents-pending in more than 40 countries. It has received…

ThursdayFeb 15, 2018 4:10 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Utilizes Oral Digestion Technology to Expand Product Line

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently announced its entry into a licensing agreement with Cannfections Group Inc. The agreement offers Lexaria the ability to provide commercial clients with high quality chocolate edibles using its proprietary DehydraTECH™ oral digestion technology. An article discussing the company reads: “Lexaria has developed various products for demonstration, testing and sales, showing wide applicability. These non-psychoactive cannabinoid products have a high-absorption hemp oil formula, are an excellent source of omegas and essential fatty acids and are engineered for physiological performance and recovery. APIs within Lexaria’s products have been shown to reduce anxiety and stress while…

MondayFeb 12, 2018 12:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expanding Best-in-Class Product Line

Lexaria has developed an oral digestion technology that may translate into lower dosages and shorter treatment regimens Company is expanding its edible product offerings through a licensing agreement with a Canadian cannabis chocolate manufacturer Lexaria continues to develop products for demonstration, testing and sales Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed DehydraTECH™, an oral digestion technology believed to improve the absorption rates of nicotine, non-steroid anti-inflammatory drugs (NSAIDs), vitamins and cannabinoids by as much as five to ten times the normal rate. The time of onset is also reduced, and effects are felt within 15 to 20 minutes…

TuesdayFeb 06, 2018 12:10 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement to Create Cannabis-infused Edibles Utilizing DehydraTECH™ Delivery Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently entered an agreement with a cannabis-infused edibles manufacturer, Cannfections Group Inc. The agreement is expected to generate new cannabis-based edible products using Lexaria’s patented DehydraTECH™ delivery technology. An article discussing the agreement reads: “On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had entered into a seven-year agreement with Cannfections Group Inc. to provide its patented DehydraTECH™ technology for the development of a new range of cannabis-infused chocolates and gummies (http://ibn.fm/U8Xb2). Cannfections is a new company, established by one of Canada’s leading chocolate manufacturers with over 85 years…

FridayFeb 02, 2018 1:28 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement with Cannabis-Infused Edibles Manufacturer

Lexaria enters agreement with Cannfections to develop an innovative range of cannabis-infused chocolates and gummies incorporating its proprietary technology, DehydraTECH™ Cannfection’s formulation and manufacturing expertise can be offered to other Lexaria licensee partners The agreement is expected to generate new cannabis-based edible products for domestic and international markets On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had entered into a seven-year agreement with Cannfections Group Inc. to provide its patented DehydraTECH™ technology for the development of a new range of cannabis-infused chocolates and gummies (http://ibn.fm/qpGlF). Cannfections is a new company, established by one of…

MondayJan 29, 2018 12:38 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential to Lower Medication Doses Using Advanced Drug Delivery

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has developed DehydraTECH™, a drug delivery platform that can be applied to various ingestible products such as foods, beverages, oral suspensions, tablets, capsules and more. An article discussing the company’s innovative drug delivery technology reads: “Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP